Drug Profile


Alternative Names: Amlodipine/rosuvastatin/fimasartan; BKC-004; Fimasartan/amlodipine/rosuvastatin; Fimasartan/rosuvastatin/amlodipine; Rosuvastatin/amlodipine/fimasartan; Rosuvastatin/fimasartan/amlodipine

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Hypertension

Most Recent Events

  • 30 May 2017 Boryung Pharmaceuticals completes a phase I trial in Hypertension and Hyperlipidemia (In volunteers) in South Korea (PO) (NCT02995720)
  • 29 May 2017 Phase-III clinical trials in Dyslipidaemias and Hypertension in South Korea (PO) (NCT03156842)
  • 19 May 2017 Boryung Pharmaceutical plans a phase III trial for Hypertension and Dyslipidaemias (NCT03156842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top